AstraZeneca receives positive high level results from Phase III I CAN trial

(Sharecast News) - Drugmaker AstraZeneca said on Tuesday that high‑level results from an interim analysis of its Phase III I CAN trial showed Ultomiris had met its primary endpoint, delivering a statistically significant and meaningful reduction in proteinuria in adults with IgA nephropathy at risk of disease progression. AstraZeneca said the main efficacy measure - changes in estimated glomerular filtration rates - would be assessed at week 106.

IgA nephropathy is a rare inflammatory kidney condition that can lead to chronic and ultimately end‑stage disease. The FTSE 100-listed company highlighted that more than 560,000 people were diagnosed with the condition across the US, EU5 and Japan - with over 60% eligible for treatment.

AstraZeneca also stated it would seek accelerated approval in key markets and that it will present the trial's results at a forthcoming medical meeting.

As of 0845 BST, AstraZeneca shares were down 1.15% at 14,780p.





Reporting by Iain Gilbert at Sharecast.com

See latest RNS at Investegate